The global RNA based therapeutic market size is calculated at USD 9.46 billion in 2025 and is expected to reach around USD 40 ...

A high-quality genome assembly of Silene latifolia was generated by researchers at CNRS/Université Claude Bernard Lyon 1 and ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...